Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on December 1, 2008. The report discloses a material event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to severance compensation for a departing executive.
Material Changes
On December 1, 2008, Al Gianchetti, Senior Vice President and Chief Commercial Officer, terminated his employment with the company. This departure is the primary material change reported in this filing.
Management Commentary and Unusual Items
Pursuant to Mr. Gianchetti's employment agreement and in exchange for a release of all claims, the company agreed to the following severance benefits:
- A cash payment equivalent to 12 months of his monthly base salary.
- Payment of his monthly COBRA health insurance premiums for 12 months.
- A lump-sum cash payment of $76,700.
The filing contains no forward-looking guidance, risk factors, or contingencies beyond the terms of this specific severance agreement.
Investor Verification Checklist
- Verify the total cash outflow impact of the 12-month salary continuation and the $76,700 lump sum on the company's cash position.
- Confirm the timeline for the appointment of a replacement Chief Commercial Officer.
- Review the company's most recent 10-Q or 10-K for baseline financial health, as this 8-K does not contain operational financial data.